Dr. Richon is a scientifically trained executive with leadership experience in small biotechnology companies, global pharmaceutical companies and academia.  Currently, Dr. Richon is the President and CEO of Ribon Therapeutics, a biotechnology company focused on the discovery and development of new cancer medicines.  Before joining Ribon, Dr. Richon was the Vice President and Global Head of Oncology Research and Translational Medicine at Sanofi where she was responsible for the oncology drug discovery and translational medicine portfolio. Prior to Sanofi, Dr. Richon was Vice President of Biological Sciences at Epizyme, Inc., a biotechnology company pioneering the discovery and development of first-in-class therapeutics focused upon epigenetics, including the EZH2 inhibitor tazemetostat.  Earlier in her career, she was Founder and Executive Director of Aton Pharmaceuticals which was acquired by Merck & Co.  Aton was formed to develop HDAC inhibitors, including vorinostat, the first HDAC inhibitor approved by the FDA.

Dr. Richon received her PhD in Biochemistry at the University of Nebraska Medical Center and a BA in Chemistry at the University of Vermont.